東華科技(002140.SZ):貴州東華增加註冊資本及股權集中
格隆匯 12 月 30日丨東華科技(002140.SZ)公佈,經公司三屆九次董事會審議通過,公司出資510萬元,聯合原貴州省化工醫藥規劃設計院管理和技術骨幹人員,共同設立貴州東華工程股份有限公司(“貴州東華”)。(詳見於2008年6月21日披露的《關於投資設立貴州東華工程股份有限公司公吿》)。
目前,貴州東華正在開展生產經營模式改革工作,經各位股東協商並達成一致,通過送紅股、認繳註冊資本等方式增加貴州東華的註冊資本;同時成立員工持股平台“貴州乾東企業管理合夥企業(普通合夥)”(“貴州乾東”),實現自然人股東股權集中。送紅股、認繳後,貴州東華註冊資本從1000萬元增加到5000萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.